Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-09-2018 | Original Paper

COMT and GAD1 gene polymorphisms are associated with impaired antisaccade task performance in schizophrenic patients

Authors: Anna V. Kirenskaya, Zinaida I. Storozheva, Marina A. Gruden, Robert D. E. Sewell

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 6/2018

Abstract

Genetic influences modulating executive functions engaging prefrontal cortical brain systems were investigated in 141 male subjects. The effects of variations in two genes implicated in dopamine and GABA activities in the prefrontal cortex: rs4680 (Val158/Met polymorphism of the catechol-o-methyltransferase gene—COMT) and rs3749034 (C/T) substitution in the promoter region of the glutamic acid decarboxylase gene (GAD1) were studied on antisaccade (AS) performance in healthy subjects and schizophrenic patients. Genotyping revealed a trend towards a reduced proportion of COMT Val/Met heterozygotes and a significantly increased frequency of the GAD1 rs3749034 C allele in schizophrenic patients relative to controls. Patients had elevated error rates, increased AS latencies and increased latency variability (coefficient of variation) compared to controls. The influence of polymorphisms was observed only in patients but not in controls. A substantial effect of the COMT genotype was noted on the coefficient of variation in latency, and this measure was higher in Val homozygotes compared to Met allele carriers (p < 0.05) in the patient group. The outcome from rs3749034 was also disclosed on the error rate (higher in T carriers relative to C homozygotes, p < 0.01) and latency (increased in C homozygotes relative to T carriers, p < 0.01). Binary logistic regression showed that inclusion of the genotype factor (i.e., selective estimation of antisaccade measures in CC carriers) considerably increased the validity of the diagnostic model based on the AS measures. These findings may well be derived from specific genetic associations with prefrontal cortex functioning in schizophrenia.

Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50:825–844. https://doi.org/10.1016/S0006-3223(01)01252-5 CrossRefPubMed

Manoach DS (2003) Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 60:285–298. https://doi.org/10.1016/S0920-9964(02)00294-3 CrossRefPubMed

Eisenberg DP, Berman KF (2010) Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacol 35:258–277. https://doi.org/10.1038/npp.2009.111 CrossRef

Goldman-Rakic S (1999) The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46:650–661. https://doi.org/10.1016/S0006-3223(99)00130-4 CrossRefPubMed

Tan H-Y, Callicott JH, Weinberger DR (2009) Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry 14:277–298. https://doi.org/10.1080/13546800903091665 CrossRefPubMed

Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, Glahn D, Finkelstein J, Hietanen M, Kaprio J, Koskenvuo M (2000) The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 67:369–382. https://doi.org/10.1086/303006 CrossRefPubMedPubMedCentral

Toulopoulou T, Picchioni M, Rijsdijk F, Hua-Hall M, Ettinger U, Sham P, Murray R (2007) Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry 64:1348–1355. https://doi.org/10.1001/archpsyc.64.12.1348 CrossRefPubMed

Gottesman I, Gould T (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636–645. https://doi.org/10.1176/appi.ajp.160.4.636 CrossRefPubMed

Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818–827. https://doi.org/10.1038/nrn1993 CrossRefPubMed

10.

Tan H-Y, Callicot JH, Weinberger DR (2008) Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? Mol Psychiatry 13:233–238. https://doi.org/10.1038/sj.mp.4002145 CrossRefPubMed

11.

Ira E, Zanoni M, Ruggeri M, Dazzan P, Tosato S (2013) COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J Psychiatry Neurosci 38:366–380. https://doi.org/10.1503/jpn.120178 CrossRefPubMedPubMedCentral

12.

Hutton SB, Ettinger U (2006) The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology 43:302–313. https://doi.org/10.1111/j.1469-8986.2006.00403.x CrossRefPubMed

13.

Broerse A, Crawford TJ, den Boer JA (2001) Parsing cognition in schizophrenia using saccadic eye movements: a selective overview. Neuropsychologia 39:742–756. https://doi.org/10.1016/S0028-3932(00)00155-X CrossRefPubMed

14.

Levy DL, Mendell NR, Holzman PS (2004) The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations. World Psychiatry 3:32–40PubMedPubMedCentral

15.

Doricchi F, Perani D, Incoccia C, Grassi F, Cappa SF, Bettinardi V, Galati G, Pizzamiglio L, Fazio F (1997) Neural control of fast-regular saccades and antisaccades: an investigation using positron emission tomography. Exp Brain Res 116:50–62. https://doi.org/10.1007/PL00005744 CrossRefPubMed

16.

Curtis CE, D’Esposito M (2003) Success and failure suppressing reflexive behavior. J Cogn Neurosci 15:409–418. https://doi.org/10.1162/089892903321593126 CrossRefPubMed

17.

Brown MR, Vilis T, Everling S (2007) Frontoparietal activation with preparation for antisaccades. J Neurophysiol 98:1751–1762. https://doi.org/10.1152/jn.00460.2007 CrossRefPubMed

18.

O’Driscoll GA, Alpert NM, Matthysse SW, Levy DL, Rauch SL, Holzman PS (1995) Functional neuroanatomy of antisaccade eye movements investigated with positron emission tomography. Proc Natl Acad Sci USA 92, 925–929CrossRefPubMed

19.

McDowell JE, Dyckman KA, Austin BP, Clementz BA (2008) Neurophysiology and neuroanatomy of reflexive and volitional saccades: evidence from studies of humans. Brain Cogn 68:255–270. https://doi.org/10.1016/j.bandc.2008.08.016 CrossRefPubMedPubMedCentral

20.

Everling S, Krappmann P, Flohr H (1997) Cortical potentials preceding pro- and antisaccades in man. Electroencephalogr. Clin Neurophysiol 102:356–362. https://doi.org/10.1016/S0013-4694(96)96569-4 CrossRef

21.

Klein C, Heinks T, Andresen B, Berg P, Moritz S (2000) Impaired modulation of the saccadic contingent negative variation preceeding antisaccades in schizophrenia. Biol Psychiatry 47:978–990. https://doi.org/10.1016/S0006-3223(00)00234-1 CrossRefPubMed

22.

Kirenskaya AV, Myamlin VV, Novototsky-Vlasov VY, Pletnikov MV, Kozlovskaya IB (2011) The contingent negative variation laterality and dynamics in antisaccade task in normal and unmedicated schizophrenic subjects. Span J Psychol 14:869–883. https://doi.org/10.5209/rev_SJOP.2011.v14.n2.34 CrossRefPubMed

23.

Amador N, Schlag-Rey M, Schlag J (2004) Primate antisaccade. II. Supplementary eye field neuronal activity predicts correct performance. J Neurophysiol 91(4):1672–1689. https://doi.org/10.1152/jn.00138.2003 CrossRefPubMed

24.

Johnston K, Everling S (2008) Neurophysiology and neuroanatomy of reflexive and voluntary saccades in nonhuman primates. Brain Cogn 68:271–283. https://doi.org/10.1016/j.bandc.2008.08017 CrossRefPubMed

25.

Schlag-Rey M, Amador N, Sanchez H, Schlag J (1997) Antisaccade performance predicted by neuronal activity in the supplementary eye field. Nature 390(6658):398–401CrossRefPubMed

26.

Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007) Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33:69–94. https://doi.org/10.1093/schbul/sbl060 CrossRefPubMed

27.

Demily C, Louchart-de-la-Chapelle S, Nkam I, Ramoz N, Denise P, Nicolas A, Savalle C, Thibaut F (2016) Does COMT val158met polymorphism influence P50 sensory gating, eye tracking or saccadic inhibition dysfunctions in schizophrenia? Psychiatry Res 246:738–744. https://doi.org/10.1016/j.psychres.2016.07.066 CrossRefPubMed

28.

Ettinger U, Kumari V, Collier DA, Powell J, Luzi S, Michel TM, Zedomi O, Williams SC (2008) Catechol-O-methyltransferase (COMT) val158met genotype is associated with BOLD response as a function of task characteristic. Neuropsychopharmacol 33:3046–3057. https://doi.org/10.1038/sj.npp.1301658 CrossRef

29.

Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2010) Catechol-O-methyltransferase Val158Met polymorphism and antisaccade eye movements in schizophrenia. Schizophr Bull 36:157–164. https://doi.org/10.1093/schbul/sbn064 CrossRefPubMed

30.

Kattoulas E, Evdokimidis I, Stefanis NC, Avramopoulos D, Stefanis CN, Smyrnis N (2010) Monitoring antisaccades: inter-individual differences in cognitive control and the influence of COMT and DRD4 genotype variations. Exp Brain Res 203:453–463. https://doi.org/10.1007/s00221-010-2250-2 CrossRefPubMed

31.

Dickinson D, Elvevåg B (2009) Genes, cognition and brain through a COMT lens. Neuroscience 164:72–87. https://doi.org/10.1016/j.neuroscience.2009.05.014 CrossRefPubMedPubMedCentral

32.

Lin JR, Cai Y, Zhang Q, Zhang W, Nogales-Cadenas R, Zhang ZD (2016) Integrated post-GWAS analysis sheds new light on the disease mechanisms of schizophrenia. Genetics. 204(4):1587–1600. https://doi.org/10.1534/genetics.116.187195 CrossRefPubMedPubMedCentral

33.

Boyle EA, Li YI, Pritchard JK (2017) An expanded view of complex traits: from polygenic to omnigenic. Cell 169(7):1177–1186. https://doi.org/10.1016/j.cell.2017.05.038 CrossRefPubMedPubMedCentral

34.

Tunbridge EM, Harrison PJ, Weinberger DR (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60:141–151. https://doi.org/10.1016/j.biopsych.2005.10.024 CrossRefPubMed

35.

Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807–821. https://doi.org/10.1086/425589 CrossRefPubMedPubMedCentral

36.

Meyer-Lindenberg A, Nichols T, Callicott H, Ding J, Kolachana B, Buckholtz J, Mattat VS, Egan M, Weinberger DR (2006) Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 11:867–877. https://doi.org/10.1038/sj.mp.4001860 CrossRefPubMed

37.

Heinz A, Smolka MN (2006) The effects of catechol O-methyltransferase genotype on brain activation elicited by affective stimuli and cognitive tasks. Rev Neurosci 17:359–367. https://doi.org/10.1515/REVNEURO.2006.17.3.359 CrossRefPubMed

38.

McIntosh AM, Baig BJ, Hall J, Job D, Whalley HC, Lymer GK, Moorhead TW, Owens DG, Miller P, Porteous D, Lawrie SM, Johnstone EC (2007) Relationship of catechol-O-methyltransferase variants to brain structure and function in a population at high risk of psychosis. Biol Psychiatry 61:1127–1134. https://doi.org/10.1016/j.biopsych.2006.05.020 CrossRefPubMed

39.

Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y, Iida H, Noguchi H, Nakabayashi T, Hori H, Ohmori M, Tsukue R, Anami K, Hirabayashi N, Harada S, Arima K, Saitoh O, Kunugi H (2006) The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 129:399–410. https://doi.org/10.1093/brain/awh702 CrossRefPubMed

40.

Lew SE, Tseng KY (2014) Dopamine modulation of GABAergic function enables network stability and input selectivity for sustaining working memory in a computational model of the prefrontal cortex. Neuropsychopharmacology 39(13):3067–3076. https://doi.org/10.1038/npp.2014.160 CrossRefPubMedPubMedCentral

41.

Akbarian S, Huang HS (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52:293–304. https://doi.org/10.1016/j.brainresrev.2006.04.001 CrossRefPubMed

42.

Benes FM. Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1–27. https://doi.org/10.1016/S0893-133X(01)00225-1 CrossRefPubMed

43.

Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS (2010) Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 167:1479–1488. https://doi.org/10.1176/appi.ajp.2010.09060784 CrossRefPubMed

44.

Hashimoto T, Arion D, Unger T, Maldonado-Avilés JG, Morris HM, Volk DW, Mirnics K, Lewis DA (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13:147–161. https://doi.org/10.1038/sj.mp.4002011 CrossRefPubMed

45.

Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324. https://doi.org/10.1038/nrn1648 CrossRefPubMed

46.

Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB (2005) Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 57:252–260. https://doi.org/10.1016/j.biopsych.2004.10.019 CrossRefPubMed

47.

Volk DW, Sampson AR, Zhang Y, Edelson JR, Lewis DA (2016) Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders. Psychol Med 46:2501–2512. https://doi.org/10.1017/S0033291716001446 CrossRefPubMedPubMedCentral

48.

Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, Greenstein D, Lenane M, Gochman P, Baker N, Balkissoon R, Vakkalanka RK, Weinberger DR, Rapoport JL, Straub RE (2005) GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 10:581–588. https://doi.org/10.1038/sj.mp.4001599 CrossRefPubMed

49.

Brauns S, Gollub RL, Walton E, Hass J, Smolka MN, White T, Wassink TH, Calhoun VD, Ehrlich S (2013) Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus. J Psychiatr Res 47:872–879. https://doi.org/10.1016/j.jpsychires.2013.03.010 CrossRefPubMedPubMedCentral

50.

Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, Mayhew MB, Vakkalanka RK, Kolachana BS, Kleinman JE, Weinberger DR (2007) Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 129:854–869. https://doi.org/10.1038/sj.mp.4001988 CrossRef

51.

Lett TA, Kennedy JL, Radhu N, Dominguez LG, Chakravarty MM, Nazeri A, Farzan F, Walter H, Heinz A, Mulsant BH, Daskalakis ZJ, Voineskos AN (2016) Prefrontal white matter structure mediates the influence of GAD1 on working memory. Neuropsychopharmacology 41:2224–2231. https://doi.org/10.1038/npp.2016.14 CrossRefPubMedPubMedCentral

52.

De Young CG, Clark R (2012) The gene in its natural habitat: the importance of gene-trait interactions. Devel Psychopathol 24:1307–1318. https://doi.org/10.1017/S0954579412000727 CrossRef

53.

Biederman J, Kim JW, Doyle AE, Mick E, Fagerness J, Smoller JW, Faraone SV (2008) Sexually dimorphic effects of four genes (COMT, SLC6A2, MAOA, SLC6A4) in genetic associations of ADHD: A preliminary study. Am J Med Genet B Neuropsychiatr Genet 147B:1511–1518. https://doi.org/10.1002/ajmg.b.30874 CrossRefPubMedPubMedCentral

54.

Tucker DM, Williamson PA (1984) Asymmetric neural control system in human self-regulation. Psychol Review 91:185–215 N 1CrossRef

55.

Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL (2014) Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res 152:503–512. https://doi.org/10.1016/j.schres.2013.12.004 CrossRefPubMedPubMedCentral

56.

Hoenicka J, Garrido E, Martínez I, Ponce G, Aragüés M, Rodríguez-Jiménez R, España-Serrano L, Alvira-Botero X, Santos JL, Rubio G, Jiménez-Arriero M, Palomo T (2010) Gender-specific COMT Val158Met polymorphism association in spanish schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 153B(1):79–85. https://doi.org/10.1002/ajmg.b.30957 PubMedCrossRef

57.

Costas J, Sanjuán J, Ramos-Ríos R, Paz E, Agra S, Ivorra JL, Páramo M, Brenlla J, Arrojo M (2011) Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis. J Psychiatr Res 45:7–14. https://doi.org/10.1016/j.jpsychires.2010.04.021 CrossRefPubMed

58.

Smyrnis N, Evdokimidis I, Stefanis NC, Avramopoulos D, Constantinidis TS, Stavropoulos A, Stefanis CN (2003) Antisaccade performance of 1,273 men: effects of schizotypy, anxiety, and depression. J Abnorm Psychol 112:403–414. https://doi.org/10.1037/0021-843X.112.3.403 CrossRefPubMed

59.

Smyrnis N, Karantinos T, Malogiannis I, Theleritis C, Mantas A, Stefanis NC, Hatzimanolis J, Evdokimidis I (2009) Larger variability of saccadic reaction times in schizophrenia patients. Psychiatry Res 168:129–136. https://doi.org/10.1016/j.psychres.2008.04.015 CrossRefPubMed

60.

Karantinos T, Tsoukas E, Mantas A, Kattoulas E, Stefanis NC, Evdokimidis I, Smyrnis N (2014) Increased intra-subject reaction time variability in the volitional control of movement in schizophrenia. Psychiatry Res 215:26–32. https://doi.org/10.1016/j.psychres.2013.10.031 CrossRefPubMed

61.

Schall JD (2002) The neural selection and control of saccades by the frontal eye field. Phil. Trans Roy Soc Lond B 357(1424):1073–1082. https://doi.org/10.1098/rstb.2002.1098 CrossRef

62.

Fukushima J, Morita N, Fukushima K, Chiba T, Tanaka S, Yamashita I (1990) Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders. J Psychiatr Res 24:9–24. https://doi.org/10.1016/0022-3956(90)90021-H CrossRefPubMed

63.

Slavutskaya MV, Kirenskaya AV,, Kozlovskaya IB (2005) Novototskiĭ-Vlasov VYu, Shul’govskiĭ VV. Slow potentials of the brain before saccades in response to visual stimuli in schizophrenic patients. Hum Physiol 31:545–553. https://doi.org/10.1007/s10747-005-0095-z CrossRef

64.

Gale HJ, Holzman PS (2000) A new look at reaction time in schizophrenia. Schizophr Res 46:149–165. https://doi.org/10.1016/S0920-9964(00)00006-2 CrossRefPubMed

65.

Curtis CE, Calkins ME, Iacono WG (2001) Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. A parametric study of the effects of increasing inhibitory load. Exp Brain Res 137:228–236. https://doi.org/10.1007/s002210000635 CrossRefPubMed

66.

Kirenskaya AV, Storozheva ZI, Kolobov VV, Sherstnev VV (2015) The acoustic startle response and polymorphism of the gene for catechol-O-methyltransferase in the norm and in schizophrenia. Neurochem J 9(1):76–83. https://doi.org/10.1134/S1819712415010031 CrossRef

Title: COMT and GAD1 gene polymorphisms are associated with impaired antisaccade task performance in schizophrenic patients
Authors: Anna V. Kirenskaya
Zinaida I. Storozheva
Marina A. Gruden
Robert D. E. Sewell
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 6/2018
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0881-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

COMT and GAD1 gene polymorphisms are associated with impaired antisaccade task performance in schizophrenic patients

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort

Identification of putative second genetic hits in schizophrenia carriers of high-risk copy number variants and resequencing in additional samples

Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics

Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?

The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride

Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial)